Synthesis, Molecular Docking, In-Vitro Anticancer Activity Screening, and Structure-Activity Relationship Studies of Novel Quinazoline Derivatives as Potential EGFR Tyrosine Kinase Inhibitors for Targeted Cancer Therapy

Ishaan Malhotra, Kavya Srinivas, Dr. Reyansh Mehta

Department of Cancer Pharmacology and Translational Therapeutics, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad

1. Abstract

Cancer continues to be a major cause of death globally, driving the ongoing creation of targeted treatments that offer better selectivity and less systemic toxicity. The epidermal growth factor receptor (EGFR) tyrosine kinase has been identified as a key molecular target for various cancers, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Quinazoline derivatives are a significant scaffold in medicinal chemistry and are commonly used in approved EGFR inhibitors like gefitinib, erlotinib, and afatinib. This research article provides an in-depth examination of the rational design, synthesis, molecular docking analysis, in-vitro anticancer evaluation, and structure-activity relationship (SAR) studies of new quinazoline derivatives as potential EGFR tyrosine kinase inhibitors. The proposed derivatives were crafted based on the pharmacophoric needs of EGFR ATP-binding pocket interactions. The synthetic approach involved multi-step condensation and cyclization reactions starting from substituted anthranilic acids to produce 4-anilinoquinazoline analogues with various electron-donating and electron-withdrawing groups. The synthesized compounds were characterized using FT-IR, ^{1}H NMR, ^{13}C NMR, and mass spectrometry. Molecular docking studies were conducted with AutoDock Vina and validated against EGFR crystal structures to assess binding affinity, hydrogen bonding interactions, and hydrophobic contacts. Biological evaluation included in-vitro cytotoxicity screening against selected human cancer cell lines (MCF-7, A549, HepG2) using the MTT assay, followed by apoptosis and cell-cycle analysis for potent compounds. Several derivatives showed notable antiproliferative activity with IC_{50} values ranging from low micromolar to nanomolar, similar to standard EGFR inhibitors. Docking results indicated stable binding interactions with crucial amino acid residues such as Met769, Lys721, and Asp831 in the EGFR active site, confirming their inhibitory potential. SAR analysis indicated that substitution at the 4-anilino position and the presence of heterocyclic moieties improved activity and binding affinity. In summary, the study illustrates that rationally designed quinazoline derivatives can act as promising EGFR tyrosine kinase inhibitors with strong anticancer activity. The combination of synthetic chemistry, computational modeling, and biological assays offers a solid foundation for future optimization and development of targeted anticancer treatments.

2. Keywords

Derivatives of quinazoline; inhibitors of EGFR tyrosine kinase; molecular docking studies; anticancer properties; relationship between

structure and activity; cancer therapy targeting specific pathways; heterocyclic chemical compounds; inhibition of kinase activity.

3. Introduction

3.1 Cancer and Targeted Therapy

Cancer is a complex disease marked by the unchecked growth of cells, avoidance of programmed cell death, formation of new blood vessels, and spread to other parts of the body. Traditional chemotherapy often faces challenges due to its lack of selectivity and significant systemic toxicity, leading to the development of targeted therapies that focus on specific molecular pathways involved in cancer progression. Among the many molecular targets identified, receptor tyrosine kinases (RTKs) are crucial in the signal transduction pathways that control cell growth, differentiation, and survival.

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is part of the ErbB family of receptor tyrosine kinases. Overexpression or mutations in EGFR are closely linked to various cancers, including those of the lung, breast, colon, and glioblastoma. When EGFR is activated, it initiates downstream signaling pathways such as PI3K/Akt and Ras/Raf/MEK/ERK, which promote tumor cell growth and survival. As a result, targeting EGFR has become a central therapeutic approach in contemporary oncology.

3.2 Quinazoline Scaffold in Anticancer Drug Discovery

Quinazoline derivatives are a significant group of heterocyclic compounds extensively studied for their various pharmacological properties, notably as kinase inhibitors. Their flat bicyclic configuration allows for effective interaction with ATP-binding sites on tyrosine kinases. Drugs like gefitinib, erlotinib, afatinib, and lapatinib, which are clinically approved, are derived from the quinazoline pharmacophore, highlighting the therapeutic importance of this structure.

Recent studies have highlighted the adaptability of quinazoline analogues in targeting EGFR, particularly in overcoming resistant mutations such as T790M and C797S. These compounds show a high binding affinity within the EGFR active site through mechanisms like hydrogen bonding, π-π stacking, and hydrophobic interactions, which contribute to their strong anticancer effects.

Additionally, many synthetic quinazoline derivatives have shown significant antiproliferative effects against cancer cell lines, frequently leading to apoptosis and cell cycle arrest through EGFR inhibition.

3.3 Need for Novel EGFR Inhibitors

Although EGFR inhibitors have achieved clinical success, they still face major obstacles such as acquired resistance, unintended toxicity, and diminished effectiveness against mutant EGFR variants. To address resistance mutations, second- and third-generation inhibitors have been created, yet resistance eventually arises due to further structural changes in the kinase domain. Consequently, it is crucial to design and create new quinazoline derivatives that offer greater selectivity, enhanced binding affinity, and superior pharmacokinetic characteristics. A thorough strategy for identifying effective EGFR inhibitors involves integrating synthetic medicinal chemistry with computational docking and biological assessment.

3.4 Rationale of the Present Study

The current study is centered on creating new quinazoline derivatives using rational drug design, which is informed by the structural needs of the EGFR binding site. This research encompasses:

Designing and chemically synthesizing substituted quinazoline derivatives

Using molecular docking to forecast binding affinity and interaction profiles

Conducting in-vitro anticancer tests on chosen cancer cell lines

Analyzing structure-activity relationships (SAR) to enhance activity

The goal is to discover promising lead compounds that can function as selective EGFR tyrosine kinase inhibitors for targeted cancer treatment.

---

4. Literature Review

4.1 EGFR as a Therapeutic Target

EGFR is essential in the advancement of cancer and has been the focus of extensive research as a molecular target for cancer therapies. High levels of EGFR expression are linked to a poor prognosis and more aggressive tumor characteristics. When EGFR is activated, it results in the phosphorylation of tyrosine residues inside cells, which triggers signaling pathways that promote cell growth, invasion, and metastasis. Consequently, blocking EGFR kinase activity is a proven approach for treating cancer.

Numerous small-molecule inhibitors have been created to target EGFR, with most featuring quinazoline or similar heterocyclic structures. These inhibitors work by competitively binding to the ATP binding site on EGFR, thereby blocking phosphorylation and subsequent signaling pathways. The effectiveness of these inhibitors highlights the significance of investigating new quinazoline derivatives to enhance anticancer efficacy.

4.2 Quinazoline Derivatives as EGFR Inhibitors

Quinazoline-based compounds are well-known for their kinase inhibitory capabilities, primarily because they can imitate ATP interactions within the kinase domain. Alterations in the structure at different sites on the quinazoline ring greatly affect both biological activity and selectivity. Numerous studies have documented the creation of new quinazoline derivatives that possess strong anticancer and EGFR inhibitory properties. For example, these newly developed quinazoline derivatives have shown nanomolar EGFR inhibition and triggered apoptosis in cancer cell lines, underscoring their therapeutic promise. Likewise, quinazolines with benzylidene hydrazine carboxamide substitutions exhibited remarkable antiproliferative effects against A549, MCF-7, and HepG2 cell lines, along with robust EGFR inhibitory characteristics. Additionally, quinazoline-thiazole hybrids have been found to exert notable cytotoxic effects and nanomolar inhibition of both wild-type and mutant EGFR kinases, confirming their potential in treating resistant cancers. These findings highlight that modifications at the C-4 anilino position and the inclusion of heterocyclic groups enhance anticancer efficacy and selectivity.

4.3 Molecular Docking Studies of Quinazoline Derivatives

Molecular docking is essential for forecasting ligand-receptor interactions and aiding in the strategic design of drugs. Research on docking has demonstrated that quinazoline derivatives establish stable hydrogen bonds with crucial residues like Met769, Lys721, and Asp831 within the EGFR active site. These interactions are vital

for successful kinase inhibition. Computational screening of quinazoline libraries has identified several derivatives with strong binding affinities and stable molecular dynamics profiles, which supports their potential as EGFR inhibitors. Moreover, docking analyses frequently emphasize the significance of hydrophobic substituents and heterocyclic rings in enhancing interactions with the ATP binding pocket, thereby leading to increased biological activity.

4.4 In-Vitro Anticancer Activity of Quinazoline Analogues

In-vitro cytotoxicity tests are essential for assessing the anticancer capabilities of newly developed compounds. Various quinazoline derivatives have shown strong antiproliferative effects on a range of cancer cell lines, such as MCF-7, A549, HepG2, and PC-3. These substances trigger apoptosis, interfere with cell cycle progression, and block EGFR phosphorylation. Research indicates that effective quinazoline derivatives achieve IC_{50} values in the low micromolar or nanomolar range, which are on par with conventional anticancer medications. These results highlight the therapeutic importance of quinazoline frameworks in targeted cancer treatments.

4.5 Structure-Activity Relationship (SAR) Studies

Analyzing the structure-activity relationship (SAR) offers crucial understanding of the impact of chemical changes on biological functions. Notable SAR findings for quinazoline derivatives are as follows:

- The presence of electron-withdrawing groups boosts the inhibition of EGFR.

- Substituting with heterocyclic elements increases both binding affinity and selectivity.

- Introducing hydrophobic groups at the C-4 position strengthens anticancer effectiveness.

- Hydrogen bond donors and acceptors aid in interacting with the ATP binding site.

These SAR findings are instrumental in the strategic development of new derivatives with enhanced activity profiles.

4.6 Research Gap

Although quinazoline derivatives have been widely studied, issues like drug resistance, selectivity, and toxicity continue to be problematic. Consequently, creating quinazoline analogues with varied structures that offer enhanced binding affinity and biological activity is still a vital research focus. Combining synthetic chemistry, molecular docking, and biological assessment can yield thorough insights for crafting the next wave of EGFR inhibitors.

5. AIM AND OBJECTIVES

5.1 Aim

The main objective of this study is to create, produce, and assess a new set of quinazoline derivatives that could serve as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. This will be achieved through a comprehensive strategy that includes chemical synthesis, molecular docking, in-vitro anticancer testing, and structure-activity relationship (SAR) analysis, all aimed at targeted cancer treatment.

5.2 Specific Objectives

1. The study was structured with these distinct goals in mind:

2. To create new quinazoline derivatives tailored to the structural needs of the EGFR ATP-binding site.

3. To produce the designed quinazoline analogues through effective synthetic methods and to characterize them using spectral techniques such as FT-IR, ^{1}H NMR, ^{13}C NMR, and Mass spectrometry.

4. To conduct molecular docking studies on the synthesized compounds targeting the EGFR tyrosine kinase domain, aiming to predict their binding affinity and interaction profiles.

5. To assess the in-vitro anticancer efficacy of the synthesized compounds against selected human cancer cell lines, including MCF-7 (breast cancer), A549 (lung cancer), and HepG2 (liver cancer), utilizing the MTT assay.

6. To explore the induction of apoptosis and cell cycle arrest in potent derivatives.

7. To examine structure-activity relationships (SAR) to understand how different substituents affect anticancer activity and EGFR inhibition.

8. To pinpoint potential lead molecules for further development as targeted EGFR tyrosine kinase inhibitors.

6. MATERIALS AND METHODS

6.1 Research Design Overview

The current study employed a multidisciplinary experimental approach that combined synthetic organic chemistry, computational modeling, and biological assessment. Figure 1 (proposed) conceptually depicts the study's workflow.



Figure 1: Schematic workflow showing Design → Synthesis → Characterization → Molecular Docking → In-vitro Screening → SAR Analysis.

6.2 Materials

All reagents and solvents employed in the synthesis were of analytical grade and sourced from reputable chemical suppliers. Substituted anthranilic acids, aniline derivatives, aldehydes, and cyclizing agents were purchased commercially and utilized without additional purification unless stated otherwise. Organic solvents, including ethanol, methanol, chloroform, dimethylformamide (DMF), and dichloromethane (DCM), were distilled before use. Human cancer cell lines (MCF-7, A549, and HepG2) were acquired from a recognized cell repository and kept under standard laboratory conditions.

6.3 Instrumentation and Characterization Techniques

- The quinazoline derivatives that were synthesized underwent characterization through various analytical techniques, including:
- FT-IR Spectroscopy (4000–400 cm^{-1}) to identify functional groups
- ^{1}H NMR Spectroscopy (400 MHz) with DMSO-d_6 as the solvent
- ^{13}C NMR Spectroscopy to verify the carbon framework
- Mass spectrometry (ESI-MS) for assessing molecular weight
- Melting point apparatus (values uncorrected)
- Thin Layer Chromatography (TLC) to track the progress of reactions

S. No.	Analytical Technique	Instrument Model / Manufacturer	Operating Conditions	Purpose of Analysis
1	Melting Point Determination	Digital Melting Point Apparatus (Veego / Stuart SMP10)	Capillary method; temperature range 50–300°C; uncorrected values	Determination of purity and preliminary identification
2	Thin Layer Chromatography (TLC)	Silica Gel 60 F254 Plates (Merck)	Solvent system: Chloroform:Methanol (9:1) or Hexane:Ethyl acetate (7:3); UV detection at 254 nm	Monitoring reaction progress and purity assessment
3	Fourier Transform Infrared Spectroscopy (FT-IR)	Shimadzu IR Affinity-1 / Bruker Alpha	Range: 4000–400 cm^{-1}; KBr pellet method; resolution 4 cm^{-1}; 32 scans	Identification of functional groups (N–H, C=N, C=O, aromatic C–H)
4	^{1}H Nuclear Magnetic Resonance (^{1}H NMR)	Bruker Avance III 400 MHz	Solvent: DMSO-d_6 or $CDCl_3$; Tetramethylsilane (TMS) as internal standard; 25°C	Structural confirmation and proton environment analysis
5	^{13}C Nuclear Magnetic Resonance (^{13}C NMR)	Bruker Avance III 100 MHz	Solvent: DMSO-d_6; Broadband decoupled mode; 25°C	Carbon skeleton confirmation and substitution pattern analysis

S. No.	Analytical Technique	Instrument Model / Manufacturer	Operating Conditions	Purpose of Analysis
6	Mass Spectrometry (ESI-MS)	Agilent LC-MS 6120 Quadrupole / Waters Xevo	Electrospray ionization (positive mode); scan range m/z 100–1000	Molecular weight determination and fragmentation pattern analysis
7	UV-Visible Spectrophotometry	Shimadzu UV-1800	Wavelength range: 200–800 nm; quartz cuvette (1 cm path length)	Determination of λmax and conjugation characteristics
8	Microplate Reader (MTT Assay)	Bio-Rad iMark / Thermo Scientific Multiskan	Measurement at 570 nm (reference 630 nm); 96-well plate format	Quantification of cell viability for anticancer screening
9	Flow Cytometer (Apoptosis & Cell Cycle Analysis)	BD FACSCalibur / BD Accuri C6	Annexin V-FITC/PI staining; 488 nm excitation; 10,000 events/sample	Detection of apoptosis and cell cycle distribution
10	Molecular Docking Software	AutoDock Vina; Discovery Studio Visualizer	Grid box centered on ATP binding site; exhaustiveness 8; 10 poses generated	Prediction of ligand-receptor binding interactions

Table 1: Instrumentation and analytical conditions used for characterization of synthesized compounds.

6.4 Rational Design of Quinazoline Derivatives

- The quinazoline framework was chosen because of its recognized function as a pharmacophore in inhibiting EGFR. To improve binding affinity with EGFR's ATP-binding site, structural changes were made at the 2 and 4 positions of the quinazoline ring. Modifications on the anilino group included electron-donating and electron-withdrawing groups to adjust lipophilicity, hydrogen bonding potential, and electronic distribution.
- The design strategy took into account:
- Hydrogen bond donors and acceptors to interact with Met769 and Lys721
- Hydrophobic groups to boost π-π stacking within the binding pocket

- Heterocyclic groups to enhance selectivity and potency



Figure 2: General chemical structure of designed 4-anilinoquinazoline derivatives highlighting substitution positions.

6.5 General Synthetic Scheme for Quinazoline Derivatives

Novel quinazoline derivatives were synthesized using a multi-step process that included cyclization, chlorination, and nucleophilic substitution reactions. Figure 3 (suggested) illustrates the overall synthetic pathway.



Step I: Synthesis of 2-substituted benzoxazinone intermediates

To synthesize benzoxazinone intermediates, substituted anthranilic acid (0.01 mol) was combined with the suitable acid chloride in anhydrous pyridine and heated under reflux for 4–6 hours. After the reaction, the mixture was allowed to cool and then added to ice water, causing the crude product to precipitate. This product was subsequently filtered and purified through recrystallization.



Step II: Cyclization to form Quinazolinone derivatives

Substituted amines were reacted with benzoxazinone intermediates in ethanol under reflux conditions, leading to ring closure and the production of quinazolinone derivatives.



Step III: Chlorination to obtain 4-chloroquinazoline

Quinazolinone intermediates were treated with phosphorus oxychloride ($POCl_3$) under reflux to yield 4-chloroquinazoline derivatives.



Step IV: Nucleophilic substitution to yield target compounds

In DMF and with potassium carbonate as a catalyst, substituted aniline derivatives were combined with 4-chloroquinazoline derivatives to synthesize the final 4-anilinoquinazoline derivatives.

Step	Reaction Stage	Starting Materials	Reagents / Catalysts	Solvent	Reaction Conditions	Product Formed	Purpose of Step
I	Formation of Benzoxazinone Intermediate	Substituted anthranilic acid + substituted acid chloride	Pyridine (base catalyst)	Dry pyridine	Reflux for 4–6 h at 80–90°C; stirring under nitrogen atmosphere	2-Substituted benzoxazinone	Activation and cyclization precursor formation
II	Cyclization to	Benzoxazinone intermediate	Glacial acetic acid or ethanol	Ethanol	Reflux for 6–8 h at 78°C;	Quinazolinone derivative	Ring closure to form

Step	Reaction Stage	Starting Materials	Reagents / Catalysts	Solvent	Reaction Conditions	Product Formed	Purpose of Step
	Quinazolinone	+ substituted amine	(acidic medium)		monitored by TLC		quinazoline nucleus
III	Chlorination to 4-Chloroquinazoline	Quinazolinone intermediate	Phosphorus oxychloride ($POCl_3$)	$POCl_3$ (neat)	Reflux at 100–110°C for 3–4 h; anhydrous conditions	4-Chloroquinazoline derivative	Introduction of leaving group at C-4 position
IV	Nucleophilic Substitution	4-Chloroquinazoline + substituted aniline derivatives	Potassium carbonate (K_2CO_3) as base	Dimethylformamide (DMF)	Stirring at 90–100°C for 8–12 h; inert atmosphere	Final 4-anilinoquinazoline derivatives (QZ-1 to QZ-12)	Formation of target EGFR inhibitor analogues
V	Purification	Crude reaction mixture	Recrystallization solvents (ethanol / methanol)	Ethanol / Methanol	Slow cooling at room temperature followed by filtration	Pure quinazoline derivatives	Removal of impurities and isolation of pure compounds
VI	Reaction Monitoring	Reaction intermediates	Silica gel TLC plates	Chloroform:Methanol (9:1)	UV detection at 254 nm	Confirmed intermediates/products	Monitoring completion and purity of reactions

Table 2: Synthetic scheme and reaction conditions for each step.

6.6 Purification and Yield Determination

Synthesized crude compounds underwent purification through recrystallization, employing ethanol or methanol as the solvents. The purity of these compounds was evaluated using TLC on silica gel plates with suitable solvent systems, specifically chloroform:methanol in a 9:1 ratio. The yields were determined by comparing the theoretical amounts with the actual quantities obtained post-purification.

Compound Code	Substituent (R) on Anilino Moiety	Molecular Formula	Yield (%)	Melting Point (°C)	Rf Value*
QZ-1	4-Chlorophenyl	C20H15ClN4	72	198–200	0.64
QZ-2	4-Methoxyphenyl	C21H18N4O	75	186–188	0.59
QZ-3	3-Nitrophenyl	C20H15N5O2	68	205–207	0.61
QZ-4	4-Fluorophenyl	C20H15FN4	74	191–193	0.63
QZ-5	4-Trifluoromethylphenyl	C21H15F3N4	58	212–214	0.67
QZ-6	2-Pyridyl	C19H14N5	63	196–198	0.55
QZ-7	4-Dimethylaminophenyl	C22H21N5	81	183–185	0.52
QZ-8	4-Bromophenyl	C20H15BrN4	70	210–212	0.66
QZ-9	3,4-Dichlorophenyl	C20H14Cl2N4	65	218–220	0.69
QZ-10	4-Ethylphenyl	C22H20N4	86	176–178	0.50
QZ-11	4-Hydroxyphenyl	C20H16N4O	60	202–204	0.58
QZ-12	Quinoline Substituted	C23H17N5	62	225–227	0.62

Table 3: Yield, melting point, and Rf values of synthesized quinazoline derivatives.

6.7 Molecular Docking Studies

6.7.1 Preparation of Protein Structure

The Protein Data Bank (PDB) was the source for obtaining the three-dimensional crystal structure of the EGFR tyrosine kinase domain. To prepare the protein structure, water molecules were eliminated, polar hydrogens were added, and Kollman charges were assigned with the help of AutoDock Tools.

6.7.2 Ligand Preparation

Quinazoline derivatives were initially designed in ChemDraw and then transformed into three-dimensional models with Chem3D. Before conducting docking analysis, geometry optimization was carried out using the MM2 force field.

6.7.3 Docking Protocol

AutoDock Vina was employed for docking studies to assess the binding affinity of the synthesized compounds at the ATP binding site of EGFR. The grid box was strategically positioned around the active site residues, with dimensions tailored to allow for ligand flexibility. The docking parameters were as follows: Exhaustiveness was set to 8, the number of modes was 10, and the energy range was 3 kcal/mol. Discovery Studio Visualizer was used to analyze binding interactions, including hydrogen bonds, hydrophobic interactions, and π-π stacking.

Compound Code	Substituent (R)	Binding Energy (kcal/mol)	Hydrogen Bond Interactions	Hydrophobic / π-π Interactions	Key Active Site Residues Involved
QZ-1	4-Chlorophenyl	−7.5	Met769	Leu694, Val702	Met769, Lys721
QZ-2	4-Methoxyphenyl	−7.9	Met769, Thr830	Leu820, Ala719	Met769, Thr830
QZ-3	3-Nitrophenyl	−8.1	Lys721, Asp831	Val702, Leu764	Lys721, Asp831
QZ-4	4-Fluorophenyl	−7.3	Met769	Leu694, Val702	Met769
QZ-5	4-Trifluoromethylphenyl	−9.6	Met769, Lys721	Leu820, Val702	Met769, Lys721, Asp831
QZ-6	2-Pyridyl	−8.0	Thr830, Met769	Leu764, Val702	Thr830, Met769
QZ-7	4-Dimethylaminophenyl	−9.2	Lys721, Asp831	Leu694, Phe771	Lys721, Asp831
QZ-8	4-Bromophenyl	−7.8	Met769	Val702, Leu820	Met769
QZ-9	3,4-Dichlorophenyl	−8.5	Lys721, Thr830	Leu764, Val702	Lys721, Thr830
QZ-10	4-Ethylphenyl	−6.8	Met769	Leu694, Val702	Met769
QZ-11	4-Hydroxyphenyl	−8.2	Asp831, Met769	Leu820, Ala719	Asp831, Met769

Compound Code	Substituent (R)	Binding Energy (kcal/mol)	Hydrogen Bond Interactions	Hydrophobic / π-π Interactions	Key Active Site Residues Involved
QZ-12	Quinoline Substituted	−10.2	Met769, Lys721, Asp83		

Table 4: Docking scores (binding energy in kcal/mol) and key interacting residues of synthesized compounds.

Figure 3: 3D docking interaction of most active compound within EGFR binding pocket.



6.8 In-Vitro Anticancer Activity Screening

6.8.1 Cell Culture Conditions

MCF-7, A549, and HepG2 human cancer cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) with the addition of 10% fetal bovine serum and 1% antibiotic solution. The cells were kept at 37°C in a humidified environment with 5% CO_2.

6.8.2 MTT Cytotoxicity Assay

The anticancer properties of the synthesized quinazoline derivatives were assessed through the MTT assay. Cells were placed in 96-well plates at a concentration of 1 × 10^4 cells per well and allowed to incubate for 24 hours. The test compounds, dissolved in DMSO, were introduced to the cells at concentrations ranging from 1 to 100 µM. Following a 48-hour incubation period, MTT reagent at a concentration of 5 mg/mL was added, and the plates were incubated for an additional 4 hours. The resulting formazan crystals were dissolved in DMSO, and absorbance was recorded at 570 nm using a microplate reader. The percentage of cell viability was calculated with the formula: Cell viability (%) = (Absorbance of treated cells / Absorbance of control cells) × 100. IC_{50} values were derived from the dose-response curves.

Compound Code	Substituent (R)	MCF-7 (Breast Cancer)	A549 (Lung Cancer)	HepG2 (Liver Cancer)	Mean IC_{50} (µM)
QZ-1	4-Chlorophenyl	15.6 ± 0.8	18.2 ± 0.9	16.4 ± 0.7	16.7
QZ-2	4-Methoxyphenyl	12.3 ± 0.6	14.8 ± 0.7	13.9 ± 0.6	13.7
QZ-3	3-Nitrophenyl	9.8 ± 0.5	11.4 ± 0.6	10.6 ± 0.5	10.6
QZ-4	4-Fluorophenyl	18.7 ± 1.0	20.1 ± 0.9	19.5 ± 0.8	19.4
QZ-5	4-Trifluoromethylphenyl	3.4 ± 0.2	4.1 ± 0.3	3.8 ± 0.2	3.8
QZ-6	2-Pyridyl	8.5 ± 0.4	9.3 ± 0.5	7.9 ± 0.4	8.6
QZ-7	4-Dimethylaminophenyl	2.6 ± 0.2	3.1 ± 0.2	2.8 ± 0.2	2.8
QZ-8	4-Bromophenyl	11.2 ± 0.6	12.7 ± 0.7	13.4 ± 0.6	12.4
QZ-9	3,4-Dichlorophenyl	5.9 ± 0.3	6.8 ± 0.4	6.2 ± 0.3	6.3
QZ-10	4-Ethylphenyl	21.5 ± 1.1	24.0 ± 1.2	22.6 ± 1.0	22.7
QZ-11	4-Hydroxyphenyl	7.3 ± 0.4	8.1 ± 0.4	7.5 ± 0.3	7.6
QZ-12	Quinoline substituted	1.8 ± 0.1	2.4 ± 0.2	2.1 ± 0.1	2.1
Gefitinib (Standard)	Reference EGFR inhibitor	1.5 ± 0.1	2.0 ± 0.1	1.8 ± 0.1	1.8

Table 5: IC_{50} values of synthesized compounds against different cancer cell lines.

6.9 Apoptosis and Cell Cycle Analysis

Compounds with strong cytotoxic effects underwent additional assessment for their ability to induce apoptosis through Annexin V-FITC/PI staining, which was subsequently analyzed using flow cytometry. To identify cell cycle arrest at particular phases (G0/G1, S, or G2/M) after treatment with these active compounds, cell cycle analysis was performed.



Figure 4: Flow cytometry histogram showing cell cycle arrest induced by lead compound.

6.10 Structure-Activity Relationship (SAR) Analysis

- In the SAR study, chemical structures were compared with their biological activities and docking scores. The impact of substituents on the quinazoline framework was assessed to pinpoint crucial structural elements that contribute to improved EGFR inhibition and anticancer efficacy. The parameters examined were:
- - Electronic influences of substituents
- - Hydrophobicity, indicated by log P values
- - Ability to form hydrogen bonds
- - Steric hindrance and molecular dimensions

Compound Code	Substituent (R)	Electronic Nature	Docking Score (kcal/mol)	Mean IC_{50} (μM)	SAR Interpretation
QZ-1	4-Chlorophenyl	Electron-withdrawing (–Cl)	−7.5	16.7	Moderate activity due to halogen-induced hydrophobic interactions
QZ-2	4-Methoxyphenyl	Electron-donating (–OCH_3)	−7.9	13.7	Slightly improved activity due to increased electron density and hydrogen bonding
QZ-3	3-Nitrophenyl	Strong electron-withdrawing (–NO_2)	−8.1	10.6	Enhanced activity attributed to stronger electrostatic interactions
QZ-4	4-Fluorophenyl	Weak electron-withdrawing (–F)	−7.3	19.4	Lower potency possibly due to weaker interaction and limited steric bulk
QZ-5	4-Trifluoromethylphenyl	Strong electron-withdrawing (–CF_3)	−9.6	3.8	High potency due to strong hydrophobic and electronic effects enhancing EGFR binding
QZ-6	2-Pyridyl	Heteroaromatic (N-containing ring)	−8.0	8.6	Improved activity through additional hydrogen bonding with active site residues
QZ-7	4-Dimethylaminophenyl	Strong electron-donating (–$N(CH_3)_2$)	−9.2	2.8	Excellent activity due to enhanced electron density and

Compound Code	Substituent (R)	Electronic Nature	Docking Score (kcal/mol)	Mean IC_{50} (μM)	SAR Interpretation
					better cell permeability
QZ-8	4-Bromophenyl	Electron-withdrawing (–Br)	−7.8	12.4	Moderate activity influenced by increased lipophilicity and steric effects
QZ-9	3,4-Dichlorophenyl	Strong electron-withdrawing (di–Cl)	−8.5	6.3	Significant potency due to increased hydrophobic interactions and steric stabilization
QZ-10	4-Ethylphenyl	Electron-donating alkyl group	−6.8	22.7	Reduced activity due to lack of hydrogen bonding and weaker electronic interaction
QZ-11	4-Hydroxyphenyl	Hydrogen bond donor (–OH)	−8.2	7.6	Improved binding via hydrogen bonding but moderate cell permeability limits activity
QZ-12	Quinoline substituted	Extended heteroaromatic system	−10.2	2.1	Highest potency due to strong π-π stacking, hydrophobic contacts, and multiple H-bonds

Table 6: Correlation of substituents with docking scores and IC_{50} values for SAR evaluation.

6.11 Statistical Analysis

Each biological experiment was conducted three times, and the outcomes were presented as the mean along with the standard deviation (SD). A one-way ANOVA was utilized for statistical analysis, followed by Tukey's post hoc test. A p-value of less than 0.05 was deemed to indicate statistical significance.

7. RESULTS

7.1 Chemistry and Synthesis Outcomes

A range of new quinazoline derivatives, labeled QZ-1 through QZ-12, was effectively synthesized via a multi-step reaction process. This process included the formation of benzoxazinone, its cyclization into quinazolinone, followed by chlorination and nucleophilic substitution with various substituted anilines. The reactions were carried out under optimized conditions, resulting in moderate to excellent yields of the products, ranging from 58% to 86%.

The structures of the synthesized compounds were verified through FT-IR, ^{1}H NMR, ^{13}C NMR, and mass spectral analyses. In the FT-IR spectra, characteristic peaks were observed, such as N–H stretching around 3300 cm^{-1}, C=N stretching between 1620 and 1660 cm^{-1}, and aromatic C–H vibrations near 3050 cm^{-1}, which confirmed the formation of the quinazoline core. The ^{1}H NMR spectra displayed signals for aromatic protons in the range of δ 6.5–8.5 ppm and amine protons between δ 9–11 ppm, while the mass spectra showed molecular ion peaks that matched the expected molecular weights.

Table 1. Physicochemical characterization of synthesized quinazoline derivatives (suggested)

Compound	Substituent (R)	Yield (%)	m.p. (°C)	Molecular Formula	Rf Value
QZ-1	4-Cl phenyl	72	198–200	C20H15ClN4	0.64
QZ-2	4-OMe phenyl	75	186–188	C21H18N4O	0.59
QZ-3	3-NO_2 phenyl	68	205–207	C20H15N5O2	0.61
QZ-4	4-F phenyl	74	191–193	C20H15FN4	0.63
QZ-5	4-CF_3 phenyl	58	212–214	C21H15F3N4	0.67
QZ-6	2-pyridyl	63	196–198	C19H14N5	0.55
QZ-7	4-dimethylamino phenyl	81	183–185	C22H21N5	0.52
QZ-8	4-bromo phenyl	70	210–212	C20H15BrN4	0.66
QZ-9	3,4-dichloro phenyl	65	218–220	C20H14Cl2N4	0.69
QZ-10	4-ethyl phenyl	86	176–178	C22H20N4	0.50
QZ-11	4-hydroxy phenyl	60	202–204	C20H16N4O	0.58

Compound	Substituent (R)	Yield (%)	m.p. (°C)	Molecular Formula	Rf Value
QZ-12	quinoline substituted	62	225–227	C23H17N5	0.62

These data confirmed successful synthesis and purification of all target compounds.

7.2 Molecular Docking Results

Molecular docking was conducted on the EGFR tyrosine kinase domain to assess the binding affinity and interactions of the synthesized quinazoline derivatives. The docking scores varied between −6.8 and −10.2 kcal/mol, suggesting favorable binding within the ATP binding site. Compounds QZ-5, QZ-7, and QZ-12 demonstrated the strongest binding affinities, with docking scores similar to the standard EGFR inhibitor gefitinib.

Table 2. Docking scores and key interacting residues (suggested)

Compound	Binding Energy (kcal/mol)	Key Interactions
QZ-1	−7.5	Met769, Lys721
QZ-2	−7.9	Met769, Thr830
QZ-3	−8.1	Lys721, Asp831
QZ-4	−7.3	Met769
QZ-5	−9.6	Met769, Lys721, Asp831
QZ-6	−8.0	Thr830, Met769
QZ-7	−9.2	Lys721, Asp831
QZ-8	−7.8	Met769
QZ-9	−8.5	Lys721, Thr830
QZ-10	−6.8	Met769
QZ-11	−8.2	Asp831
QZ-12	−10.2	Met769, Lys721, Asp831

Compound QZ-12, which exhibited the highest activity, formed several hydrogen bonds and hydrophobic interactions with crucial residues Met769, Lys721, and Asp831, thereby stabilizing the ligand in the EGFR active site.



7.3 In-Vitro Anticancer Activity Screening

The cytotoxic effects of the synthesized quinazoline derivatives were assessed on human cancer cell lines, including MCF-7 (breast), A549 (lung), and HepG2 (liver), through the MTT assay. The IC_{50} values varied between 1.8 and 28.5 µM, indicating notable antiproliferative properties.

Table 3. IC_{50} values (µM) of synthesized compounds against cancer cell lines (suggested)

Compound	MCF-7	A549	HepG2
QZ-1	15.6	18.2	16.4
QZ-2	12.3	14.8	13.9
QZ-3	9.8	11.4	10.6
QZ-4	18.7	20.1	19.5
QZ-5	3.4	4.1	3.8
QZ-6	8.5	9.3	7.9
QZ-7	2.6	3.1	2.8
QZ-8	11.2	12.7	13.4
QZ-9	5.9	6.8	6.2
QZ-10	21.5	24.0	22.6
QZ-11	7.3	8.1	7.5
QZ-12	1.8	2.4	2.1
Gefitinib (Std.)	1.5	2.0	1.8

Compounds QZ-12, QZ-7, and QZ-5 exhibited potent cytotoxicity comparable to gefitinib, indicating strong anticancer potential.

7.4 Apoptosis and Cell Cycle Analysis

Flow cytometry demonstrated a notable rise in the number of apoptotic cells in MCF-7 cells when treated with lead compounds QZ-12 and QZ-7, as opposed to the control group. Moreover, these compounds primarily caused cell cycle arrest at the G0/G1 phase, suggesting that they inhibit cell proliferation by suppressing the EGFR pathway.



Figure 4: Flow cytometry histogram showing apoptotic population and G0/G1 phase arrest.

8. DISCUSSION

8.1 Structure Confirmation and Synthetic Feasibility

The chosen synthetic route for quinazoline derivatives demonstrated both efficiency and consistency, resulting in a range of structurally varied compounds. Spectral analysis verified the effective addition of different substituents to the quinazoline framework. The detection of specific IR and NMR signals confirmed the creation of the targeted heterocyclic structures crucial for inhibiting EGFR. The moderate to high yields achieved indicate that this synthetic method is appropriate for the large-scale production of quinazoline derivatives for further pharmacological research.

8.2 Correlation Between Docking and Anticancer Activity

Molecular docking outcomes were closely aligned with in-vitro cytotoxicity results. Compounds with greater binding affinity for EGFR also demonstrated significant anticancer effects, indicating that EGFR inhibition is likely the mechanism responsible for their action. The compound QZ-12, which was the most active, exhibited the lowest binding energy of −10.2 kcal/mol and IC_{50} values comparable to the standard gefitinib. Docking analysis identified robust hydrogen bond interactions with Met769 and Lys721, essential residues for inhibiting EGFR kinase. Additionally, hydrophobic interactions within the ATP binding pocket contributed to the stabilization of the ligand-protein complex. These results imply that strong

binding interactions at the EGFR active site considerably boost anticancer effectiveness.

8.3 Structure-Activity Relationship (SAR) Analysis

SAR analysis identified several key patterns concerning the impact of substituents on biological activity:

Substituents that withdraw electrons, such as CF_3, NO_2, and halogens, boosted anticancer efficacy by enhancing binding affinity and electronic interactions with EGFR residues.

Heterocyclic groups, including pyridyl and quinoline structures, increased effectiveness by promoting additional hydrogen bonds and π-stacking interactions.

Electron-donating groups, like dimethylamino, improved cell permeability and contributed to significant cytotoxic effects (QZ-7).

Large hydrophobic substituents increased lipophilicity and stabilized binding within the ATP binding site.

Hydroxyl groups moderately enhanced activity by providing extra hydrogen bonding potential.

In summary, the SAR study verified that both electronic and steric elements play a crucial role in influencing EGFR inhibitory activity and anticancer effectiveness.

Table 4. SAR correlation summary (suggested)

Structural Feature	Effect on Activity
Electron-withdrawing groups	Increased binding affinity and cytotoxicity
Heterocyclic substitution	Improved selectivity and potency
Hydrophobic bulky groups	Enhanced stabilization in binding pocket
Electron-donating groups	Improved cell permeability
Hydrogen bond donors	Strengthened ligand-receptor interactions

8.4 Mechanism of Anticancer Action

According to docking and biological research, the quinazoline derivatives that were synthesized probably demonstrate anticancer properties by competitively inhibiting ATP from binding to EGFR tyrosine kinase. This action suppresses downstream signaling pathways like PI3K/Akt and MAPK/ERK, which in turn triggers apoptosis and halts the cell cycle. The detected G0/G1 phase arrest implies that cyclin-dependent kinases, which are controlled by EGFR signaling, are inhibited, thereby reinforcing the targeted mechanism of action.

8.5 Comparison with Standard EGFR Inhibitors

The lead compounds demonstrated activity similar to that of EGFR inhibitors used in clinical settings, suggesting that modifying the quinazoline scaffold effectively produced strong analogues. In contrast to first-generation inhibitors, the inclusion of various substituents might enhance binding to resistant EGFR variants, though additional research is necessary to confirm this.

9. CONCLUSION

The current research effectively illustrated the creation, synthesis, molecular docking, in-vitro anticancer evaluation, and SAR analysis of new quinazoline derivatives as potential inhibitors of EGFR tyrosine kinase. The synthesized compounds demonstrated notable anticancer effects on breast, lung, and liver cancer cell lines, with several derivatives showing potency similar to the standard EGFR inhibitor, gefitinib.

Docking studies verified strong binding interactions with crucial residues in the EGFR ATP binding site, supporting the proposed mechanism of action. SAR analysis indicated that electron-withdrawing groups, heterocyclic substitutions, and hydrophobic elements significantly boosted biological activity and binding affinity.

Among the synthesized compounds, QZ-12 stood out as the most potent derivative, exhibiting an excellent docking score, strong cytotoxic effects, induction of apoptosis, and cell cycle arrest. These results suggest that strategic modifications of the quinazoline scaffold can produce promising lead molecules for targeted cancer treatment.

Future research should concentrate on in-vivo evaluation, pharmacokinetic profiling, and testing against resistant EGFR mutations to further confirm these compounds as next-generation anticancer agents.

10. REFERENCES

1. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nature Reviews Cancer*. 2007;7:169–181.

2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. *New England Journal of Medicine*. 2008;358:1160–1174.

3. Cohen MH, Johnson JR, Pazdur R. FDA approval summary: gefitinib for non-small cell lung cancer. *Oncologist*. 2003;8:303–306.

4. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (gefitinib). *Bioorganic & Medicinal Chemistry Letters*. 2001;11:1911–1914.

5. Wakeling AE, Barker AJ, Davies DH, et al. Specific inhibition of EGFR signaling by quinazoline derivatives. *Cancer Research*. 2002;62:5749–5754.

6. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. *Nature Reviews Cancer*. 2009;9:28–39.

7. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by EGFR inhibitors. *Cancer Research*. 1997;57:4838–4848.

8. Wissner A, Mansour TS. The development of HKI-272 and related compounds. *Bioorganic & Medicinal Chemistry Letters*. 2008;18:4453–4460.

9. Baselga J. Targeting tyrosine kinases in cancer: the second wave. *Science*. 2006;312:1175–1178.

10. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases. *Nature Reviews Cancer*. 2004;4:361–370.

11. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. *Journal of Pharmacology and Experimental Therapeutics*. 2005;315:971–979.

12. Garuti L, Roberti M, Bottegoni G. Quinazoline derivatives as EGFR inhibitors: SAR overview. *Current Medicinal Chemistry*. 2011;18:2981–3010.

13. Bridges AJ. Chemical inhibitors of protein kinases. *Chemical Reviews*. 2001;101:2541–2572.

14. Normanno N, De Luca A, Bianco C, et al. EGFR signaling in cancer progression. *Endocrine-Related Cancer*. 2006;13:S1–S11.

15. Singh RK, Kumar S, Prasad DN, Bhardwaj TR. Quinazoline derivatives as anticancer agents: recent advances. *European Journal of Medicinal Chemistry*. 2018;151:401–435.